TPST vs. MIST, CCCC, TNYA, BYSI, HLVX, UPXI, COYA, OPTN, HURA, and IOBT
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Milestone Pharmaceuticals (MIST), C4 Therapeutics (CCCC), Tenaya Therapeutics (TNYA), BeyondSpring (BYSI), HilleVax (HLVX), Upexi (UPXI), Coya Therapeutics (COYA), OptiNose (OPTN), TuHURA Biosciences (HURA), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry.
Tempest Therapeutics vs. Its Competitors
Tempest Therapeutics (NASDAQ:TPST) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.
Tempest Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 334.78%. Milestone Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 272.34%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tempest Therapeutics is more favorable than Milestone Pharmaceuticals.
Tempest Therapeutics has a beta of -1.95, indicating that its stock price is 295% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Tempest Therapeutics had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Tempest Therapeutics and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.93 beat Tempest Therapeutics' score of 0.77 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.
Tempest Therapeutics' return on equity of -305.51% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals has higher revenue and earnings than Tempest Therapeutics. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Milestone Pharmaceuticals beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TPST) was last updated on 7/1/2025 by MarketBeat.com Staff
Free TPST Stock Alerts